BE study Design for Ri­va­rox­aban 20 mg [Design Issues]

posted by Tricky TAB – Bangladesh, 2022-07-04 13:33 (1097 d 16:16 ago) – Posting: # 23103
Views: 4,230

Hello!

The Design for Rivaroxaban 20 mg BE Study stated by US-FDA is as follows:

Single-dose, two-treatment, two-sequence, four-period, fully replicate crossover

Is it possible to go with Single-dose, two-treatment, two-sequence, two-period crossover study design?

Thank You!


Edit: Category changed; see also this post #1. Guidance linked. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,675 registered users;
20 visitors (0 registered, 20 guests [including 8 identified bots]).
Forum time: 05:49 CEST (Europe/Vienna)

Many people tend to look at programming styles and languages like religions:
if you belong to one, you cannot belong to others.
But this analogy is another fallacy.    Niklaus Wirth

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5